Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC
GLOBETECH MEDIA

Collaboration to Further Novel Cancer Immunotherapy Approach

By BiotechDaily International staff writers
Posted on 31 Mar 2014
A new immunotherapy program has been established to drastically slash cancer deaths by targeting eight cancers with the support of several new research platforms that provide infrastructure, technology, and know-how.

MedImmune (Gaithersburg, MD, USA), AstraZeneca’s (Cambridge, UK) global biologics research and development arm, has entered into a three-year translational and clinical research collaboration with The University of Texas MD Anderson Cancer Center (Houston, TX, USA) to evaluate therapies that trigger patients’ immune systems to attack their cancers through MD Anderson’s Moon Shots Program.

MedImmune is conducting clinical trials using a new therapeutic concept that targets immune cells to improve their tumor-fighting ability, rather than targeting the tumor cell itself. Through the collaboration, MD Anderson will evaluate several of MedImmune’s immunotherapy molecules in a clinical setting to better determine how these molecules elicit immune response in patients.

The scientists hope that data gathered from these studies will provide new clues on treatment-related changes to tumors, with the ultimate goal of identifying the best combination therapies and developing biomarkers to guide and assess the safety and effectiveness of MedImmune’s immunotherapy molecules.

“We are excited to work with MD Anderson in the Moon Shots program, pairing their unique immunotherapy platform with our innovative portfolio of immune-mediated cancer therapies,” said Dr. Ed Bradley, senior vice president and head of MedImmune’s oncology innovative medicines unit. “Our partnership will provide MedImmune with an invaluable opportunity to evaluate the biological impact of our immune-mediated cancer agents, both as monotherapy and combination therapy.”

“Our collaboration with MedImmune, a leader in the field of immunotherapy, will draw on the strengths of both institutions to push ahead for more effective treatments for cancer patients,” said Jim Allison, PhD, executive director of the moon shots immunotherapy platform and professor and chair of immunology at MD Anderson.

MedImmune is the worldwide biologics research and development arm of AstraZeneca, a global, innovation-driven biopharmaceutical business that focuses on the discovery, development, and commercialization of small molecule and biologic prescription medicines. MedImmune is conducting novel research and exploring pathways across key therapeutic areas, including respiratory, inflammation and autoimmunity; cardiovascular and metabolic disease; oncology; neuroscience; and infection and vaccines.

Related Links:

MedImmune
University of Texas MD Anderson Cancer Center



Channels

Genomics/Proteomics

view channel
Image: Transmission electron micrograph of norovirus particles in feces (Photo courtesy of Wikimedia Commons).

Norovirus Interacts with Gut Bacteria to Establish a Persistent Infection That Can Be Blocked by Interferon Lambda

A team of molecular microbiologists and virologists has found that norovirus requires an intimate interaction with certain gut bacteria to establish a persistent infection, and that the infective process... Read more

Biochemistry

view channel

Possible New Target Found for Treating Brain Inflammation

Scientists have identified an enzyme that produces a class of inflammatory lipid molecules in the brain. Abnormally high levels of these molecules appear to cause a rare inherited eurodegenerative disorder, and that disorder now may be treatable if researchers can develop suitable drug candidates that suppress this enzyme.... Read more

Therapeutics

view channel
Image: Cancer cells infected with tumor-targeted oncolytic virus (red). Green indicates alpha-tubulin, a cell skeleton protein. Blue is DNA in the cancer cell nuclei (Photo courtesy of Dr. Rathi Gangeswaran, Bart’s Cancer Institute).

Innovative “Viro-Immunotherapy” Designed to Kill Breast Cancer Cells

A leading scientist has devised a new treatment that employs viruses to kill breast cancer cells. The research could lead to a promising “viro-immunotherapy” for patients with triple-negative breast cancer,... Read more

Lab Technologies

view channel
Image: MIT researchers have designed a microfluidic device that allows them to precisely trap pairs of cells (one red, one green) and observe how they interact over time (Photo courtesy of Burak Dura, MIT).

New Device Designed to See Communication between Immune Cells

The immune system is a complicated network of many different cells working together to defend against invaders. Effectively combating an infection depends on the interactions between these cells.... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.